Literature DB >> 29291209

Recent advances in vaccine development against Ebola threat as bioweapon.

Prachi Gera1, Ankit Gupta1, Priyanka Verma1, Joginder Singh2, Jeena Gupta2.   

Abstract

With the increasing rate of Ebola virus appearance, with multiple natural outbreaks of Ebola hemorrhagic fever, it is worthy of consideration as bioweapon by anti-national groups. Further, with the non-availability of the vaccines against Ebola virus, concerns about the public health emerge. In this regard, this review summarizes the structure, genetics and potential of Ebola virus to be used as a bioweapon. We highlight the recent advances in the treatment strategies and vaccine development against Ebola virus. The understanding of these aspects might lead to effective treatment practices which can be applied during the future outbreaks of Ebola.

Entities:  

Keywords:  Bioweapon; Ebola hemorrhagic fever; Ebola outbreak; Ebola vaccine; Ebola virus

Year:  2017        PMID: 29291209      PMCID: PMC5685003          DOI: 10.1007/s13337-017-0398-0

Source DB:  PubMed          Journal:  Virusdisease        ISSN: 2347-3584


  34 in total

Review 1.  Biological weapons in the twentieth century: a review and analysis.

Authors:  M Leitenberg
Journal:  Crit Rev Microbiol       Date:  2001       Impact factor: 7.624

2.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors:  Larry Zeitlin; James Pettitt; Corinne Scully; Natasha Bohorova; Do Kim; Michael Pauly; Andrew Hiatt; Long Ngo; Herta Steinkellner; Kevin J Whaley; Gene G Olinger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

3.  A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.

Authors:  R N Harty; M E Brown; G Wang; J Huibregtse; F P Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

4.  The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target.

Authors:  Jonathan J Madara; Ziying Han; Gordon Ruthel; Bruce D Freedman; Ronald N Harty
Journal:  Future Virol       Date:  2015-05       Impact factor: 1.831

5.  Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner.

Authors:  Asuka Nanbo; Masaki Imai; Shinji Watanabe; Takeshi Noda; Kei Takahashi; Gabriele Neumann; Peter Halfmann; Yoshihiro Kawaoka
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

6.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Authors:  Lisa M Johansen; Jennifer M Brannan; Sue E Delos; Charles J Shoemaker; Andrea Stossel; Calli Lear; Benjamin G Hoffstrom; Lisa Evans Dewald; Kathryn L Schornberg; Corinne Scully; Joseph Lehár; Lisa E Hensley; Judith M White; Gene G Olinger
Journal:  Sci Transl Med       Date:  2013-06-19       Impact factor: 17.956

8.  Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium.

Authors:  Hanlu Fan; Xiaohong Du; Jingyuan Zhang; Han Zheng; Xiaohui Lu; Qihui Wu; Haifeng Li; Han Wang; Yi Shi; George Gao; Zhuan Zhou; Dun-Xian Tan; Xiangdong Li
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

9.  Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Mark G Lewis; Joan B Geisbert; Allen Grolla; Anders Leung; Jason Paragas; Lennox Matthias; Mark A Smith; Steven M Jones; Lisa E Hensley; Heinz Feldmann; Peter B Jahrling
Journal:  PLoS Pathog       Date:  2008-11-28       Impact factor: 6.823

10.  Plant-made pharmaceuticals: from 'Edible Vaccines' to Ebola therapeutics.

Authors:  Charles Arntzen
Journal:  Plant Biotechnol J       Date:  2015-09-08       Impact factor: 9.803

View more
  2 in total

1.  Nurses' and Medical Officers' Knowledge, Attitude, and Preparedness Toward Potential Bioterrorism Attacks.

Authors:  Confidence A Atakro; Stella B Addo; Janet S Aboagye; Alice A Blay; Kwaku G Amoa-Gyarteng; Awube Menlah; Isabella Garti; Dorcas F Agyare; Kumah K Junior; Limmy Sarpong
Journal:  SAGE Open Nurs       Date:  2019-05-03

Review 2.  Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.

Authors:  Kuldeep Dhama; Kumaragurubaran Karthik; Rekha Khandia; Sandip Chakraborty; Ashok Munjal; Shyma K Latheef; Deepak Kumar; Muthannan Andavar Ramakrishnan; Yashpal Singh Malik; Rajendra Singh; Satya Veer Singh Malik; Raj Kumar Singh; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.